Spots Global Cancer Trial Database for TERPS Trial for de Novo Oligometastic Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: TERPS Trial for de Novo Oligometastic Prostate Cancer

Official Title: Phase 2 Randomized Total Eradication of Metastatic Lesions Following Definitive Radiation to the Prostate in de Novo oligometaStatic Prostate Cancer (TERPS) Trial

Study ID: NCT05223803

Conditions

Prostate Cancer

Oligometastatic Disease

Interventions

Prostate radiation (XRT)

Systemic Therapy

Stereotactic ablative radiation therapy (SABR)

Study Description

Brief Summary: This research is being done to determine if we can improve the outcome of prostate cancer patients who have failed primary treatment - surgery or local radiation to the prostate - and have three or fewer bone or soft tissue metastases.

Detailed Description: This study will compare the effects, good and/or bad, of using the standard of care treatment (systemic therapy + primary prostate radiation) compared to standard of care treatment plus stereotactic ablative radiation therapy (SABR) to metastatic lesions for prostate patients. The researchers are also trying to learn if the addition of SABR will affect recurrence rates. Presence of circulating tumor cells, gut bacteria, and quality of life will be assessed for both groups.